ATAI Life Sciences NV
9VC
Company Profile
Business description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Contact
Wallstrasse 16
BerlinBB10179
DEUT: +49 8921539035
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
54
Stocks News & Analysis
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.30 | 60.00 | 0.68% |
| CAC 40 | 7,775.80 | 32.37 | -0.41% |
| DAX 40 | 24,098.71 | 61.93 | -0.26% |
| Dow JONES (US) | 44,216.87 | 242.78 | -0.55% |
| FTSE 100 | 8,951.58 | 46.48 | -0.52% |
| HKSE | 24,590.12 | 386.80 | 1.60% |
| NASDAQ | 20,772.97 | 132.65 | 0.64% |
| Nikkei 225 | 39,678.02 | 218.40 | 0.55% |
| NZX 50 Index | 12,689.63 | 10.94 | 0.09% |
| S&P 500 | 6,271.69 | 3.13 | 0.05% |
| S&P/ASX 200 | 8,630.30 | 59.90 | 0.70% |
| SSE Composite Index | 3,505.00 | 14.65 | -0.42% |